[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Ehehalt F, Saeger HD, Schmidt CM, Grützmann R: Neuroendocrine tumors of the pancreas. Oncologist; 2009 May;14(5):456-67
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine tumors of the pancreas.
  • This literature review briefly summarizes the epidemiology, pathophysiology, clinical management, and outcomes of patients with pancreatic neuroendocrine tumors (PNETs) and highlights recent advances in PNET research.
  • PNETs are rare neoplasms, compared with carcinomas arising from pancreatic exocrine tissue.
  • They, like other neuroendocrine tumor types, display variable malignant potential, hormone-related syndromes (functionality), localization, and genetic background.
  • Although tumor origin and molecular pathogenesis remain poorly understood, recently established grading and staging systems facilitate patient risk stratification, and thereby directly impact clinical decision making.
  • Although the optimal clinical management of PNETs involves a multidisciplinary approach, surgery remains the only curative treatment for early-stage disease.
  • Alternative therapeutic approaches applied to PNETs, including chemotherapy, radiofrequency ablation, transarterial chemoembolization, biotherapy, polypeptide radionuclide receptor therapy, antiangiogenic therapy, and selective internal radiotherapy, have failed to demonstrate a long-term survival benefit.
  • Surgery remains the primary therapeutic option for patients with PNETs.
  • Research on PNETs is desperately needed to improve the therapeutic options for patients with this disease.
  • [MeSH-major] Neuroendocrine Tumors. Pancreatic Neoplasms
  • [MeSH-minor] Gastrinoma / diagnosis. Gastrinoma / therapy. Humans. Incidence. Insulinoma / diagnosis. Insulinoma / therapy. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19411317.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 130
  •  go-up   go-down


2. Langfort R, Rudziński P, Burakowska B: [Pulmonary neuroendocrine tumors. The spectrum of histologic subtypes and current concept on diagnosis and treatment]. Pneumonol Alergol Pol; 2010;78(1):33-46
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary neuroendocrine tumors. The spectrum of histologic subtypes and current concept on diagnosis and treatment].
  • Neuroendocrine tumors of the lung represent a broad spectrum of morphologic types that share specific morphologic, immunohistochemical, ultrastructural, and molecular characteristics.
  • The classification of neuroendocrine lung tumors has changed over the last decades and currently four categories are distinguished: typical carcinoid tumor, atypical carcinoid tumor, large cell neuroendocrine carcinoma and small cell carcinoma.
  • Neuroendocrine tumors of the lung comprise approximately 20% of all primary lung cancers.
  • Because of differences in clinical behavior, therapy, and prognosis, a reliable histological diagnosis, as well as clinical and pathological staging system are essential for an appropriate medical proceedings.
  • The most effective treatment of bronchial carcinoids and large cell neuroendocrine carcinoma in an early stage is complete surgical resection, whereas chemotherapy remains the primary treatment for small cell carcinoma.
  • All carcinoids are malignant tumors with the potential to metastasize.
  • Large cell neuroendocrine and small cell carcinoma progress rapidly and are generally widespread at the moment of diagnosis.
  • Increased knowledge about pulmonary neuroendocrine tumors biology and the genetic characteristics, imply that carcinoid tumors appear to have a different etiology and pathogenesis than large cell neuroendocrine and small cell carcinoma.
  • In practice, it could be easiest to conceptualize this group of pulmonary tumors as a spectrum of malignancy ranging from the low grade typical carcinoid to the highly malignant large cell neuroendocrine and small cell carcinoma.
  • Typical carcinoid tumors associated with a fairly benign behavior should be classified as low-grade neuroendocrine tumor/carcinoma (G1) and atypical carcinoid tumors as intermediate-grade tumor/carcinoma (G2).
  • Whereas, large cell neuroendocrine and small cell carcinoma should be grouped together under the designation of high-grade neuroendocrine tumor/carcinoma (G3).
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / therapy. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / therapy
  • [MeSH-minor] Carcinoid Tumor / diagnosis. Carcinoid Tumor / therapy. Carcinoma, Large Cell / diagnosis. Carcinoma, Large Cell / therapy. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / therapy. Humans. Lung / pathology. Lymphatic Metastasis. Neoplasm Staging. Prognosis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20162517.001).
  • [ISSN] 0867-7077
  • [Journal-full-title] Pneumonologia i alergologia polska
  • [ISO-abbreviation] Pneumonol Alergol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 67
  •  go-up   go-down


3. Seya T, Tanaka N, Shinji S, Shinji E, Yokoi K, Horiba K, Kanazawa Y, Yamada T, Oaki Y, Tajiri T: Case of rectal malignant melanoma showing immunohistochemical variability in a tumor. J Nippon Med Sch; 2007 Oct;74(5):377-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case of rectal malignant melanoma showing immunohistochemical variability in a tumor.
  • We report on a patient with rectal malignant melanoma.
  • Abdominopelvic computed tomography (CT) revealed multiple liver and lymph node metastases.
  • With the diagnosis of neuroendocrine carcinoma of the rectum, abdominoperineal resection was performed.
  • Neoadjuvant chemotherapy using cisplatin and irinotecan via the subcutaneous reservoir port was performed and a partial response was obtained.
  • However, the final pathological diagnosis of the surgically resected specimen was malignant amelanotic melanoma of the rectum.
  • As preoperative pathological diagnosis showed rare rectal tumor, we measured the chemosensitivity of the rectal tumor using the collagen gel droplet-embedded culture drug sensitivity test (CD-DST) to determine the most appropriate chemotherapy regimen for the patient.
  • However, there were no anticancer drugs tested by CD-DST for malignant melanoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Melanoma / diagnosis. Neoplasm Proteins / analysis. Proto-Oncogene Proteins c-kit / analysis. Rectal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antigens, Neoplasm. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Digestive System Surgical Procedures. Drug Resistance, Neoplasm. Drug Screening Assays, Antitumor / methods. Fatal Outcome. Humans. Immunohistochemistry. Interferon-beta / administration & dosage. Male. Melanoma-Specific Antigens. Neoadjuvant Therapy. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17965534.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 77238-31-4 / Interferon-beta; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


Advertisement
4. Liang WY, Chen WY, Tsay SH, Chiang H: Desmoplastic small round cell tumor--report of 3 cases and review of the literature. Kaohsiung J Med Sci; 2000 May;16(5):261-5
Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Desmoplastic small round cell tumor (DSRCT) is a rare neoplasm with distinctive histological features, characterized by extensive stromal tissue around islands of small and undifferentiated cells revealing the desmoplastic appearance.
  • The histological and immunhistochemical features are very distinct but may be misdiagnosed as other undifferentiated neoplasm if the pathologist has no idea of this entity.
  • The first case was diagnosed as malignant neuroendocrine neoplasm orginally and revised to DSRCT later.
  • Case 2 had been diagnosed as Atypical carcinoid and received surgery and chemotherapy.
  • Case 3 carried the characteristic feature whereby diagnosis could be made even in frozen section.
  • [MeSH-minor] Adolescent. Adult. Diagnosis, Differential. Humans. Immunohistochemistry. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10969522.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


5. Lindboe CF: Large cell neuroendocrine carcinoma of the ovary. APMIS; 2007 Feb;115(2):169-76
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large cell neuroendocrine carcinoma of the ovary.
  • Large cell neuroendocrine carcinoma of the ovary is a recently described tumour entity that is now included in the WHO classification of primary ovarian neoplasms.
  • Although mostly in stage I at diagnosis, this tumour shows an aggressive clinical behaviour with subsequent metastases and mean survival is less than one year.
  • In addition to the neuroendocrine carcinoma, most cases also have a malignant surface epithelial tumour component.
  • I here report a 64-year-old woman who was operated on for a right-sided ovarian large cell neuroendocrine carcinoma without a surface epithelial component, which constitutes only the second reported tumour of this "pure" kind.
  • The patient was treated postoperatively with chemotherapy.
  • She developed bleomycin-induced lung fibrosis that responded well to treatment with steroids.
  • [MeSH-major] Carcinoma, Large Cell / pathology. Carcinoma, Neuroendocrine / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Aged. Antigens, Neoplasm / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17295684.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, Neoplasm
  •  go-up   go-down


6. Igawa S, Watanabe R, Ito I, Murakami H, Takahashi T, Nakamura Y, Tsuya A, Kaira K, Naito T, Endo M, Yamamoto N, Kameya T: Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer. Lung Cancer; 2010 Jun;68(3):438-45
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer.
  • BACKGROUND: Pulmonary large cell neuroendocrine carcinoma (LCNEC) shares several features with small cell lung carcinoma (SCLC).
  • While the diagnosis of LCNEC by biopsy specimens is challenging, a definitive diagnosis of this highly malignant tumor is critical in unresectable cases to determine the optimal therapeutic strategy.
  • The objective of this study was to assess the efficacy of chemotherapy for unresectable high-grade non-small cell neuroendocrine carcinoma (HNSCNEC) called by us, which likely includes most LCNECs except for combined types, and to compare the efficacy of chemotherapy for HNSCNEC, with that for extended disease SCLC (ED-SCLC).
  • We simultaneously evaluated the clinical response to the chemotherapy and survival time of the 14 HNSCNEC and 77 ED-SCLC patients.
  • RESULTS: The chemotherapy regimens in the 14 patients with unresectable HNSCNEC were platinum-based combination regimens or irinotecan or vinorelbine or docetaxel alone.
  • The chemotherapy regimens in the 77 patients with ED-SCLC were platinum-based combination regimens.
  • We assessed an objective response rate, a one-year survival rate, and median survival time as 50% (7/14), 34% and 10 months, respectively, in the 14 HNSCNEC patients, and as 53% (41/77), 48% and 12.3 months, respectively, in the 77 ED-SCLC patients.
  • CONCLUSION: The clinical efficacy of chemotherapy for unresectable HNSCNECs, including most LCNECs, is comparable to that for ED-SCLC.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Neuroendocrine Tumors / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Disease Progression. Drug Therapy, Combination. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Platinum Compounds / administration & dosage. Platinum Compounds / adverse effects. Survival Analysis. Taxoids / administration & dosage. Taxoids / adverse effects. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19699548.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Platinum Compounds; 0 / Taxoids; 15H5577CQD / docetaxel; 5V9KLZ54CY / Vinblastine; 7673326042 / irinotecan; Q6C979R91Y / vinorelbine; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


7. Cook MR, Pinchot SN, Jaskula-Sztul R, Luo J, Kunnimalaiyaan M, Chen H: Identification of a novel Raf-1 pathway activator that inhibits gastrointestinal carcinoid cell growth. Mol Cancer Ther; 2010 Feb;9(2):429-37
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carcinoids are neuroendocrine tumors (NET) that secrete hormones, including serotonin, resulting in the malignant carcinoid syndrome.
  • In addition to the significant morbidity associated with the syndrome, carcinoids are frequently metastatic at diagnosis, and untreated mortality at 5 years exceeds 70%.
  • Surgery is the only curative option, and the need for other therapies is clear.
  • We investigated the ability of leflunomide (LFN), a Food and Drug Administration-approved medication for the treatment of rheumatoid arthritis, and its active metabolite teriflunomide (TFN) as a potential anti-NET treatment.
  • Treatment with TFN suppresses the cellular levels of serotonin and chromogranin A, a glycopeptide co-secreted with bioactive hormones.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LEFLUNOMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hosp Med. 2000 May;61(5):344-7 [10953742.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2001 Jan;13(1):55-8 [11204811.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3200-5 [11306509.001]
  • [Cites] Surg Clin North Am. 2001 Jun;81(3):527-42 [11459269.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S69-72 [11762355.001]
  • [Cites] Chirurg. 2002 Jul;73(7):716-20 [12242982.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3512-9 [12429642.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):934-59 [12569593.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2003 Aug;285(2):G245-54 [12851216.001]
  • [Cites] Surgery. 2003 Dec;134(6):866-71; discussion 871-3 [14668716.001]
  • [Cites] Mod Pathol. 2004 Feb;17(2):222-9 [14657947.001]
  • [Cites] World J Surg. 2004 Apr;28(4):387-92 [14994141.001]
  • [Cites] Clin Ther. 2004 Apr;26(4):447-59 [15189743.001]
  • [Cites] Surg Gynecol Obstet. 1973 Oct;137(4):637-44 [4730072.001]
  • [Cites] Arthritis Rheum. 1995 Nov;38(11):1595-603 [7488280.001]
  • [Cites] Biochem Pharmacol. 1996 Aug 23;52(4):527-34 [8759024.001]
  • [Cites] Surgery. 1996 Aug;120(2):168-72; discussion 173 [8751579.001]
  • [Cites] Cell Growth Differ. 1997 Jun;8(6):677-86 [9186001.001]
  • [Cites] Ann Oncol. 1997 Jul;8(7):685-90 [9296223.001]
  • [Cites] J Am Coll Surg. 1998 Jul;187(1):88-92; discussion 92-3 [9660030.001]
  • [Cites] J Immunol. 1999 Feb 15;162(4):2095-102 [9973483.001]
  • [Cites] Transplantation. 1999 Jul 15;68(1):100-9 [10428276.001]
  • [Cites] Biochem Pharmacol. 1999 Nov 1;58(9):1405-13 [10513984.001]
  • [Cites] Mol Cancer Ther. 2005 Jun;4(6):910-7 [15956248.001]
  • [Cites] Thyroid. 2005 Jun;15(6):511-21 [16029117.001]
  • [Cites] Curr Opin Oncol. 2006 Jan;18(1):9-15 [16357558.001]
  • [Cites] Anticancer Drugs. 2006 Feb;17(2):139-42 [16428931.001]
  • [Cites] Mol Biotechnol. 2006 Mar;32(3):227-48 [16632889.001]
  • [Cites] Surg Oncol Clin N Am. 2006 Jul;15(3):463-78 [16882492.001]
  • [Cites] Semin Oncol. 2006 Aug;33(4):392-406 [16890795.001]
  • [Cites] Anticancer Drugs. 2006 Aug;17(7):849-53 [16926634.001]
  • [Cites] Surgery. 2006 Dec;140(6):1009-14; discussion 1014-5 [17188151.001]
  • [Cites] Oncogene. 2007 May 14;26(22):3279-90 [17496922.001]
  • [Cites] Biochim Biophys Acta. 2007 Aug;1773(8):1299-310 [17188374.001]
  • [Cites] Oncologist. 2007 Aug;12(8):942-51 [17766653.001]
  • [Cites] Surgery. 2007 Dec;142(6):959-64; discussion 959-64 [18063082.001]
  • [Cites] Leukemia. 2008 Mar;22(3):635-8 [17805332.001]
  • [Cites] Cell Signal. 2008 Jul;20(7):1349-58 [18450423.001]
  • [Cites] Int MS J. 2008 Jun;15(2):62-8 [18782502.001]
  • [Cites] Oncologist. 2008 Dec;13(12):1255-69 [19091780.001]
  • [Cites] Ann Surg Oncol. 2009 Feb;16(2):481-6 [19030935.001]
  • [Cites] Mol Cancer Ther. 2009 Feb;8(2):366-75 [19174558.001]
  • [Cites] Am J Surg. 2009 Mar;197(3):313-9 [19245907.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • (PMID = 20103603.001).
  • [ISSN] 1538-8514
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA121115-01A2; United States / NCI NIH HHS / CA / CA109053-03; United States / NCI NIH HHS / CA / CA109053-04; United States / NCI NIH HHS / CA / R01 CA109053-03; United States / NCI NIH HHS / CA / R01 CA121115; United States / NCI NIH HHS / CA / R01 CA109053; United States / NCI NIH HHS / CA / R01 CA109053-04; United States / NCI NIH HHS / CA / R01CA121115
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chromogranin A; 0 / Crotonates; 0 / Isoxazoles; 0 / Toluidines; 1C058IKG3B / teriflunomide; 333DO1RDJY / Serotonin; EC 2.7.11.1 / Proto-Oncogene Proteins c-raf; G162GK9U4W / leflunomide
  • [Other-IDs] NLM/ NIHMS167835; NLM/ PMC2820603
  •  go-up   go-down


8. Rammer M, Kirchgatterer A, Höbling W, Stockhammer M, Knoflach P: [W.D.H.A. Syndrome due to occult neuroendocrine malignancy with concomitant liver metastases]. Z Gastroenterol; 2003 Feb;41(2):185-9
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [W.D.H.A. Syndrome due to occult neuroendocrine malignancy with concomitant liver metastases].
  • [Transliterated title] Okkulte, maligne neuroendokrine Neoplasie mit Lebermetastasen als Ursache eines WDHA-Syndroms.
  • The biopsy of the liver shows a malignant neuroendocrine tumour.
  • In the absence of clinical symptoms a wait and see procedure with clinical and imaging controls at regular intervals is arranged.
  • Beginning in spring of 2001--nearly two years after the initial diagnosis--the patient suffers from progredient diarrhoea and weight loss leading to hospitalisation in September 2001.
  • A vipoma is a rare differential diagnosis of secretory diarrhoea.
  • This case report describes the remarkable constellation of liver metastases of a malignant neuroendocrine neoplasm without a primary tumour and the clinical presentation of a W.D.H.A. syndrome (watery diarrhoea, hypokalaemia and hypo- or achlorhydria).
  • Despite extensive disease, therapy with octreotide and prednisolone provides a good clinical response.
  • [MeSH-major] Liver Neoplasms / secondary. Neoplasms, Unknown Primary / diagnosis. Vipoma / secondary
  • [MeSH-minor] Biopsy, Needle. Diagnosis, Differential. Diagnostic Imaging. Humans. Liver / pathology. Male. Middle Aged. Octreotide / administration & dosage. Prednisolone / administration & dosage. Radioligand Assay. Receptors, Somatostatin / analysis. Vasoactive Intestinal Peptide / blood. Water-Electrolyte Balance / drug effects

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12592602.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Receptors, Somatostatin; 37221-79-7 / Vasoactive Intestinal Peptide; 9PHQ9Y1OLM / Prednisolone; RWM8CCW8GP / Octreotide
  •  go-up   go-down


9. Andrés R, Mayordomo JI, Ramón y Cajal S, Tres A: Paraneoplastic Cushing's syndrome associated to locally advanced thymic carcinoid tumor. Tumori; 2002 Jan-Feb;88(1):65-7
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histology and immunohistochemistry allow differential diagnosis from other epithelial thymic tumors, such as thymomas and thymic carcinomas.
  • The term used to name this tumor is confusing, since it is a malignant neuroendocrine neoplasm, and therapeutic approaches need to bear that in mind.
  • CASE REPORT: Unlike most cases of thymic carcinoid associated to Cushing's syndrome that had distant metastases at diagnosis, we report a 50-year-old male who presented with Cushing's syndrome and was diagnosed with thymic carcinoid without distant metastases.
  • Multimodal treatment with surgery, radiotherapy and chemotherapy (cisplatin plus etoposide) induced a complete clinical and biochemical remission lasting for 46 months.
  • [MeSH-minor] Adrenocorticotropic Hormone / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromogranin A. Chromogranins / metabolism. Cisplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Humans. Immunoenzyme Techniques. Male. Middle Aged. Radiotherapy Dosage


10. Rhemtula H, Grayson W, van Iddekinge B, Tiltman A: Large-cell neuroendocrine carcinoma of the uterine cervix--a clinicopathological study of five cases. S Afr Med J; 2001 Jun;91(6):525-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large-cell neuroendocrine carcinoma of the uterine cervix--a clinicopathological study of five cases.
  • OBJECTIVE: The present study describes 5 cases of large-cell neuroendocrine carcinoma (LCNEC) of the uterine cervix, evaluating their clinical features and pathological profiles.
  • A histopathological diagnosis was obtained after biopsy material from all 5 patients was examined microscopically and subjected to immunohistochemical staining with MNF116 (pankeratin) synaptophysin and chromagranin A, all of which are neuroendocrine markers.
  • None of the 5 patients in this series received chemotherapy or underwent surgery.
  • Treatment responses and long-term survival in our series proved to be disappointing as 3 of the 5 patients died in less than 6 months.
  • On histopathological examination, all 5 tumours showed features of a high-grade poorly differentiated malignant neoplasm with ulceration and extensive tumour necrosis including trabecular and organoid growth patterns.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Parity. Prognosis. Survival Analysis. Synaptophysin. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11455720.001).
  • [ISSN] 0256-9574
  • [Journal-full-title] South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
  • [ISO-abbreviation] S. Afr. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] South Africa
  • [Chemical-registry-number] 0 / Synaptophysin
  •  go-up   go-down


11. Veras E, Deavers MT, Silva EG, Malpica A: Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases. Am J Surg Pathol; 2007 May;31(5):774-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases.
  • Nonsmall cell neuroendocrine carcinoma (NSCNEC) of the ovary is a rare and aggressive tumor commonly associated with other surface epithelial and germ cell neoplasms.
  • In 8 cases, NSCNEC was associated with other epithelial neoplasms, including mucinous neoplasms of low malignant potential, mucinous carcinoma, endometrioid carcinoma, mixed endometrioid and mucinous carcinoma, and a high-grade carcinoma, not otherwise specified.
  • Microscopically, the neuroendocrine component was usually composed of large and/or intermediate oval to round cells.
  • Seven patients were treated with total abdominal hysterectomy and bilateral salpingo-oophorectomy followed by chemotherapy.
  • One patient had a bilateral salpingo-oophorectomy with omentectomy and appendectomy followed by chemotherapy; 1 patient had a total abdominal hysterectomy with right salpingo-oophorectomy followed by chemotherapy; one had a bilateral salpingo-oophorectomy followed by chemotherapy, and one had a right salpingo-oophorectomy with appendectomy followed by chemotherapy.
  • In summary, ovarian NSCNEC is an aggressive tumor with a tendency to present at advanced stage and cause death within a mean of 17 months after diagnosis; however, some patients, particularly those with stage I disease and/or those who have received platinum-based therapy, may have a more favorable prognosis.
  • [MeSH-major] Biomarkers, Tumor. Carcinoma, Neuroendocrine / pathology. Immunoenzyme Techniques. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Staging. Neoplasms, Multiple Primary. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460463.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


12. Patnaik AK, Post GS, Erlandson RA: Clinicopathologic and electron microscopic study of cutaneous neuroendocrine (Merkel cell) carcinoma in a cat with comparisons to human and canine tumors. Vet Pathol; 2001 Sep;38(5):553-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic and electron microscopic study of cutaneous neuroendocrine (Merkel cell) carcinoma in a cat with comparisons to human and canine tumors.
  • Malignant neuroendocrine carcinoma of the skin (Merkel cell tumor) was diagnosed in an 18-year-old spayed female Maine Coon Cat.
  • The diagnosis was made on the basis of morphologic and electron microscopic findings.
  • [MeSH-major] Carcinoma, Merkel Cell / veterinary. Cat Diseases / pathology. Neoplasm Recurrence, Local / veterinary. Skin Neoplasms / veterinary
  • [MeSH-minor] Animals. Cats. Diagnosis, Differential. Dogs. Fatal Outcome. Female. Humans. Immunohistochemistry / veterinary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lung Neoplasms / veterinary. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / secondary. Mediastinal Neoplasms / veterinary. Microscopy, Electron / methods. Microscopy, Electron / veterinary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11572564.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Raderer M, Kurtaran A, Scheithauer W, Fiebiger W, Weinlaender G, Oberhuber G: Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid. Oncology; 2001;60(2):141-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid.
  • We report the case of a patient with a disseminated carcinoid, who progressed during dose-intensified treatment with slow-release LAN in combination with interferon-alpha, but developed a pronounced response after treatment was switched to the application of a depot formulation of OCT.
  • After a diagnosis of metastatic carcinoid had been established, treatment with LAN (30 mg i.m. every 10 days) along with interferon-alpha 3 x 5 MU/week was initiated.
  • As she refused chemotherapy, treatment was switched to a depot formulation of OCT (20 mg i.m. every 4 weeks), resulting both in a disappearance of symptoms as well as tumor regression as seen on CT scanning.
  • CONCLUSION: To our knowledge, this is the first case demonstrating both a symptomatic as well as objective response to OCT following progression during therapy with LAN in a patient with a carcinoid tumor.
  • Our results suggest that refractoriness to treatment including a long-acting SST analogue does not automatically imply resistance to a related agent and should alert clinicians to the potential of non-cross-resistance between SST analogues in neuroendocrine malignancies.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Bone Neoplasms / drug therapy. Carcinoid Tumor / drug therapy. Octreotide / therapeutic use. Pancreatic Neoplasms / drug therapy. Peptides, Cyclic / therapeutic use. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use
  • [MeSH-minor] Drug Resistance, Neoplasm. Female. Humans. Middle Aged. Radionuclide Imaging. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11244329.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Peptides, Cyclic; 0G3DE8943Y / lanreotide; 51110-01-1 / Somatostatin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


14. Huang GS, Chang WC, Lee HS, Taylor JA, Cheng TY, Chen CY: Merkel cell carcinoma arising from the subcutaneous fat of the arm with intact skin. Dermatol Surg; 2005 Jun;31(6):717-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Merkel cell carcinoma is a rare malignant neuroendocrine neoplasm characteristically arising from the dermis of sunlight-exposed skin.
  • The patient received wide excision of the lesion with dissection of the regional lymph nodes and adjuvant radiotherapy and chemotherapy.
  • RESULTS: Histopathologic examination confirmed the diagnosis of Merkel cell carcinoma with local lymphatic metastasis, and the lesion was completely located in the subcutaneous fat, with no involvement of the dermis.
  • [MeSH-major] Carcinoma, Merkel Cell / diagnosis. Neoplasms, Adipose Tissue / surgery. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15996429.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Yamamoto R, Hosokawa S, Yamatodani T, Morita S, Okamura J, Mineta H: [Eight cases of neuroendcrine carcinoma of the head and neck]. Nihon Jibiinkoka Gakkai Kaiho; 2008 Jul;111(7):517-22
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Small cell neuroendocrine carcinoma of the head and neck is rare, and diagnosis may be difficult.
  • We reported eight cases of stage IV small cell neuroendocrine carcinoma of the head and neck, all in men with a mean onset age of 62 years (range: 45 to 80 years).
  • Histological analysis by hematoxylin-eosin staining tentatively revealed malignant lymphoma and undifferentiated carcinoma in two cases each, while immunohistological and/or electron microscopy analysis confirmed histological diagnosis.
  • All were treated by chemotherapy (VP-16, CDDP) and seven cases with radiotherapy based on the schedule of small cell carcinoma of the lung and two cases with lesional resection.
  • Chemotherapy and radiotherapy were effective locally.
  • Long-term survival thus requires the effective treatment of distant metastasis.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Carcinoma, Neuroendocrine / therapy. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Cisplatin / administration & dosage. Combined Modality Therapy. Diagnosis, Differential. Epirubicin / administration & dosage. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18697475.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; PE regimen
  •  go-up   go-down


16. Oberg K, Eriksson B: Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol; 2005 Oct;19(5):753-81
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some of the tumours may be part of multiple endocrine neoplasia type one (MEN-1) syndrome or von Hippel-Lindau (vHL) disease.
  • The biochemical diagnosis of EPT is based on hormones and amines released.
  • The location of endocrine tumours of the pancreas includes different techniques, from endoscopic investigations to scintigraphy (e.g. somatostatin receptor scintigraphy) and positron emission tomography.
  • The medical treatment of endocrine pancreatic tumours consists of chemotherapy, somatostatin analogues and alpha-interferon.
  • None of these can cure a patient with malignant disease.
  • In future, therapy will be custom-made and based on current knowledge of tumour biology and molecular genetics.
  • [MeSH-major] Carcinoma, Neuroendocrine / drug therapy. Carcinoma, Neuroendocrine / pathology. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Female. Gastrinoma / drug therapy. Gastrinoma / epidemiology. Gastrinoma / pathology. Glucagonoma / drug therapy. Glucagonoma / epidemiology. Glucagonoma / pathology. Humans. Immunohistochemistry. Incidence. Insulinoma / drug therapy. Insulinoma / epidemiology. Insulinoma / pathology. Male. Molecular Biology. Neoplasm Staging. Prognosis. Risk Assessment. Somatostatinoma / drug therapy. Somatostatinoma / epidemiology. Somatostatinoma / pathology. Survival Rate. Treatment Outcome. Zollinger-Ellison Syndrome / drug therapy. Zollinger-Ellison Syndrome / epidemiology. Zollinger-Ellison Syndrome / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253899.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 141
  •  go-up   go-down


17. De Dosso S, Bajetta E, Procopio G, Cortinovis D, Buzzoni R, Catena L, Platania M, Verzoni E: Pulmonary carcinoid tumours: indolent but not benign. Oncology; 2007;73(3-4):162-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The aim of this retrospective study was to analyse the malignant behaviour of low-grade pulmonary neuroendocrine tumours (NETs) treated at our institution.
  • RESULTS: At diagnosis, there were 37 metastatic and 11 non-metastatic patients.
  • Medical treatments used were somatostatin analogues, combined chemotherapy, within study protocols, 5-fluorouracil/dacarbazine/epiadriamycin (FDE), and oxaliplatin plus capecitabine (XELOX).
  • CONCLUSION: Cell type is the strongest determinant of prognosis, and the degree of malignancy increases from TCs to ACs.
  • Our analysis suggests that patients with advanced disease should receive first-line therapy with a somatostatin analogue, with chemotherapy regimens (FDE, XELOX) used in progressing cases.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease Progression. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • (PMID = 18418008.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


18. Weisser H, Hartschuh W, Greiner A, Bischof M, Enk A, Helmbold P: [Merkel cell carcinoma--clinically often misjudged]. Dtsch Med Wochenschr; 2007 Jul 30;132(30):1581-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Merkel cell carcinoma is a rare, rapidly growing, highly malignant dermal tumor which occurs preferentially on light-exposed skin in advanced age.
  • The five-year overall survival rate is only about 65 %, despite rigorous therapy.
  • The histological pattern is characterized by trabecular strands of small, uniform cells with large basophilic nuclei and typical neuroendocrine granules.
  • The diagnosis is confirmed immunohistochemically by neuroendocrine and epithelial markers.
  • The excision of the primary tumor is regarded as first-line therapy.
  • Adjuvant chemotherapy can be applied in this stage, as in small-cell bronchial carcinoma.
  • Despite good response to radiatiotherapy and chemotherapy, with at least prolonged recurrence-free intervals, Merkel cell carcinoma is rarely curable at the distant metastasizing stage.
  • Individually defined, aggressive treatment,including radiatiotherapy, may in future considerably improve the prognosis, especially in the early stages of the disease.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Carcinoma, Merkel Cell / therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Skin Neoplasms / pathology. Skin Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Humans. Immunohistochemistry / methods. Lymphatic Metastasis. Neoplasm Staging. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17628844.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 50
  •  go-up   go-down


19. Varras M, Akrivis Ch, Demou A, Hadjopoulos G, Stefanaki S, Antoniou N: Primary small-cell carcinoma of the endometrium: clinicopathological study of a case and review of the literature. Eur J Gynaecol Oncol; 2002;23(6):577-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Small-cell carcinomas are almost always primary in the lungs and are highly malignant.
  • This tumor may exhibit evidence of neuroendocrine differentiation and has a high propensity for systemic spread and poor prognosis.
  • CASE: A 55-year-old postmenopausal woman with primary small-cell carcinoma of the endometrium, FIGO stage Ib, underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy and sampling node biopsies of the parametrial spaces, followed by adjuvant combined chemotherapy.
  • [MeSH-major] Carcinoma, Small Cell / diagnosis. Endometrial Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12556112.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 26
  •  go-up   go-down


20. Kurian S, Ertan E, Ducatman B, Crowell EB, Rassekh C: Esthesioneuroblastoma in Maffucci's syndrome. Skeletal Radiol; 2004 Oct;33(10):609-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Maffucci's syndrome consists of multiple cutaneous hemangiomas, dyschondroplasia, and enchondromas with potential for malignant change.
  • Radiological studies showed a large soft tissue mass centered in the sinonasal area, extending bilaterally into maxillary sinuses and orbits with compression of left optic nerve.
  • Chemotherapy resulted in initial improvement, but the tumor recurred and did not respond to further treatment, resulting in his death.
  • Sarcomatous tumors are reported in Maffucci's syndrome, but this is a rare case of a neuroendocrine tumor in a patient with Maffucci's syndrome.
  • [MeSH-major] Enchondromatosis / complications. Esthesioneuroblastoma, Olfactory / diagnosis. Nasal Cavity / pathology. Nose Neoplasms / diagnosis
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Male. Maxillary Sinus Neoplasms / diagnosis. Neoplasm Recurrence, Local / pathology. Orbital Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1999 Oct;109(10):1539-43 [10522919.001]
  • [Cites] Am J Clin Oncol. 1990 Apr;13(2):139-43 [2180272.001]
  • [Cites] Arch Otolaryngol. 1979 Jul;105(7):427-30 [454301.001]
  • [Cites] Cancer. 1989 Jun 15;63(12):2426-8 [2720589.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 Jun;15(6):1169-77 [8073990.001]
  • [Cites] Anticancer Res. 1997 Jul-Aug;17(4A):2683-706 [9252701.001]
  • [Cites] Dermatol Clin. 1995 Jan;13(1):73-8 [7712654.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1023-7; discussion 1027-8 [9588546.001]
  • [Cites] Cancer. 1976 Mar;37(3):1571-6 [1260676.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 Jan;123(1):34-40 [9006501.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1029-37 [9588547.001]
  • (PMID = 15221218.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


21. Deng GH, Zhang X, Wu LY: [Clinicopathological analysis of nine cases of small cell carcinoma of the uterine cervix]. Zhonghua Zhong Liu Za Zhi; 2010 Mar;32(3):199-202
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the clinicopathologic characteristics, therapy and prognostic factors of small cell carcinoma of the uterine cervix (SCCC).
  • Immunohistochemical staining showed at least three neuroendocrine markers (NSE, CgA, Syn and CD56) were positive in each case.
  • All patients received postoperative chemotherapy, with or without radiotherapy.
  • CONCLUSION: SCCC is a highly malignant tumor with aggressive behavior.
  • Correct diagnosis of SCCC depends on the combination of light microscopic and immunohistochemical analysis.
  • It is necessary to use multimodality treatment for SCCC, especially the chemotherapy.
  • [MeSH-minor] Adult. Antigens, CD56 / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromogranin A / metabolism. Cisplatin / therapeutic use. Combined Modality Therapy. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Female. Follow-Up Studies. Humans. Lymph Node Excision. Middle Aged. Neoplasm Staging. Phosphopyruvate Hydratase / metabolism. Radiotherapy, High-Energy. Survival Rate. Synaptophysin / metabolism. Taxoids / therapeutic use

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450588.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Chromogranin A; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Nuclear Proteins; 0 / Synaptophysin; 0 / Taxoids; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; EC 4.2.1.11 / Phosphopyruvate Hydratase; Q20Q21Q62J / Cisplatin; TP protocol
  •  go-up   go-down


22. Hage R, de la Rivière AB, Seldenrijk CA, van den Bosch JM: Update in pulmonary carcinoid tumors: a review article. Ann Surg Oncol; 2003 Jul;10(6):697-704
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pulmonary carcinoid tumors are neuroendocrine malignant tumors that make up 1% to 2% of all lung tumors.
  • Carcinoids can be placed in a spectrum of neuroendocrine tumors, ranging from low-grade malignant TC to intermediate AC to high-grade large-cell neuroendocrine carcinoma and small-cell lung carcinoma.
  • The diagnosis is usually established by flexible bronchoscopy and biopsy, although occasionally this can result in severe hemorrhage.
  • Immunoscintigraphy by somatostatin analogs can also be useful in diagnosis.
  • The treatment of choice is surgical resection, and prognosis is relatively good in TC, although it is worse in AC.
  • The role of radiotherapy and chemotherapy as part of multimodality treatment or palliation is still debated.
  • [MeSH-minor] Biopsy. Bronchoscopy. Chemotherapy, Adjuvant. Combined Modality Therapy. Cough / etiology. Fever / etiology. Hemoptysis / etiology. Humans. Neoplasm Staging. Palliative Care. Prognosis. Radioimmunodetection. Radiotherapy, Adjuvant. Respiratory Sounds / etiology. Somatostatin

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12839856.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 51110-01-1 / Somatostatin
  • [Number-of-references] 65
  •  go-up   go-down


23. Wei S, Carroll W, Lazenby A, Bell W, Lopez R, Said-Al-Naief N: Sinonasal teratocarcinosarcoma: report of a case with review of literature and treatment outcome. Ann Diagn Pathol; 2008 Dec;12(6):415-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sinonasal teratocarcinosarcoma: report of a case with review of literature and treatment outcome.
  • Sinonasal teratocarcinosarcoma is a highly malignant, polymorphous neoplasm that combines features of carcinosarcoma and teratoma.
  • Computerized tomography scans and magnetic resonance imaging revealed a large mass filling the left nasal cavity and extending to the cribriform plate with involvement of the ethmoid sinuses, lamina papyracea, and orbit.
  • The patient underwent a complex procedure for a T3N0 tumor.
  • Immature neuroepithelium and olfactory neuroblastomalike tissue are highlighted with neuroendocrine markers.
  • Postoperatively, the patient had a rapid local recurrence of the tumor and underwent reexcision, and was treated with radiotherapy and chemotherapy.
  • Twelve months after his primary resection, computerized tomography scans revealed an intrathoracic tumor with dominant mass in the left hilum and metastases to the mediastinum, left pleural space, and both lungs.
  • Among 54 cases of reported sinonasal teratocarcinosarcoma, 67% of patients with initial single surgical resection and 80% of patients primarily treated with radiotherapy had recurrence, or metastatsis, or unresponsiveness to treatment.
  • Almost half of the patients died of tumor within 3 years of diagnosis, despite aggressive therapy.
  • Seventy percent of the patients who survived more than 1 year had the initial therapeutic regiments of combined surgery and adjuvant therapies, suggesting that aggressive therapeutic approaches may improve the treatment outcome.
  • [MeSH-major] Carcinosarcoma / diagnosis. Carcinosarcoma / therapy. Nose Neoplasms / diagnosis. Nose Neoplasms / therapy. Teratoma / diagnosis. Teratoma / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Paranasal Sinuses / pathology. Paranasal Sinuses / surgery. Prognosis. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18995206.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


24. Scherübl H, Klöppel G: [Rectal carcinoids on the rise - update]. Z Gastroenterol; 2009 Apr;47(4):365-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Neuroendokrine Neoplasien des Rektums auf dem Vormarsch - ein Update.
  • This dramatic increase is probably related to the introduction of colonoscopic screening which also results in the "incidentally" detected neuroendocrine rectal tumours/carcinomas being smaller than in the pre-screening era.
  • Neuroendocrine rectal neoplasms (rectal carcinoids) of 10.1 - 20 mm in diameter have a metastasis risk of 17 - 42 (81) % for neuroendocrine rectal neoplasms > 20 mm in size this risk increases to 60 - 80 %.
  • A carcinoid syndrome is rarely observed, even in cases of distant metastases of neuroendocrine rectal carcinomas.
  • Stable somatostatin analogues and interferon-alpha constitute the drug therapies of choice for carcinoid syndrome.
  • As a result of the increasing early detection of rectal carcinoids/carcinomas the prognosis for the patients has improved considerably in the last 30 years.
  • In addition to the early detection of colorectal adenoma and adenocarcinoma, screening colonoscopy also makes possible the early detection and early therapy for neuroendocrine rectal tumours/carcinomas.
  • [MeSH-minor] Colonoscopy. Cross-Sectional Studies. Endosonography. Humans. Incidence. Incidental Findings. Intestinal Mucosa / pathology. Malignant Carcinoid Syndrome / diagnosis. Malignant Carcinoid Syndrome / epidemiology. Malignant Carcinoid Syndrome / pathology. Malignant Carcinoid Syndrome / therapy. Mass Screening. Neoplasm Invasiveness / pathology. Prognosis

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19358064.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 41
  •  go-up   go-down


25. Quaedvlieg PF, Visser O, Lamers CB, Janssen-Heijen ML, Taal BG: Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol; 2001 Sep;12(9):1295-300
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Carcinoid tumours are rare malignant neuroendocrine tumours.
  • In 1992 octreotide was introduced in the Netherlands as a palliative treatment for the carcinoid syndrome in metastatic carcinoid disease.
  • Incidence of distant metastases at diagnosis for appendix and lung primary sites was 1.6% and 5.5%, compared to 40%, in the other primary sites.
  • In metastatic disease, however, only year of diagnosis after 1992 independently predicted survival (P = 0.012).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11697843.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; RWM8CCW8GP / Octreotide
  •  go-up   go-down






Advertisement